본문 바로가기

바이오스펙테이터

기사본문

Oscotec, “successfully conducting clinical trial for 3 candidates”

입력 2017-11-20 10:51 수정 2017-12-08 10:53

바이오스펙테이터 Joungmin Cho 기자

이 기사는 '프리미엄 뉴스서비스 BioS+' 기사입니다.
Research Director, Kim Jung-ho introduces main pipeline at the 5th bio-investment forum held by Mirae Asset Daewoo

“Oscotec is focusing on finding 518 human kinases that have unmet needs, and it’s been 9 years since established a subsidiary, Genosco, in Boston where big pharma companies are located. We have tried our best efforts to develop new drugs to compete with them, and now, we are looking forward to seeing visible results soon.” Director of Research in Oscotec, Kim Jung-ho, said on the 13th at the 5th bio-Investment Forum.

Oscotec is a new drug developing company which has a pipeline being developed jointly with Yuhan, and has been conducting clinical trials for their own two pipelines in the U.S. and firstly announced their pipelines in the forum that was held jointly by Mirae Asset Daewoo and the Korea Bio Association.

Dr.Kim said, “Oscotec is a company that develops small-molecular-compound drugs and has patent (IP) rights to design and synthesize new compounds that are suitable for their own purposes. However, we are using the NRDO method outsourced with CRO for clinical developing processes.”

Oscotec is focusing on kinase. Phosphorylating enzymes are activated by ATP and continue to transmit signals to the sub-system. In abnormal conditions such as cancer, phosphorylating enzymes cause various problems by maintaining unnecessary activation....

'프리미엄 뉴스서비스 BioS+'는 독자들에게 가치(value)있는 기사를 제공합니다.
추가내용은 유료회원만 이용할 수 있습니다.
회원이시면 로그인 해주시고, 회원가입을 원하시면 클릭 해주세요.